💞 #Gate Square Qixi Celebration# 💞
Couples showcase love / Singles celebrate self-love — gifts for everyone this Qixi!
📅 Event Period
August 26 — August 31, 2025
✨ How to Participate
Romantic Teams 💑
Form a “Heartbeat Squad” with one friend and submit the registration form 👉 https://www.gate.com/questionnaire/7012
Post original content on Gate Square (images, videos, hand-drawn art, digital creations, or copywriting) featuring Qixi romance + Gate elements. Include the hashtag #GateSquareQixiCelebration#
The top 5 squads with the highest total posts will win a Valentine's Day Gift Box + $1
Novo Nordisk: 7.2mg semaglutide phase 3 clinical trial met the primary endpoint with a weight loss of 20.7% at 72 weeks.
On January 18, Jins data reported that on January 17 local time, Novo Nordisk announced the main results of the 3b phase clinical trial STEP UP. In the STEP UP obesity trial, subcutaneous injection of 7.2mg semaglutide once a week resulted in a weight loss of 20.7% at 72 weeks, and a weight loss of 18.7% regardless of treatment compliance. The trial met its primary endpoint, with 7.2mg semaglutide showing statistically significant and superior weight loss compared to placebo at 72 weeks.